Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

Rituximab 17Cyclophosphamide 8zanubrutinib 7Bendamustine Hydrochloride 7obinutuzumab 6Lenalidomide 6venetoclax 5blinatumomab 5acalabrutinib 5Vincristine 5fludarabine 4Prednisone 4Methotrexate 4Doxorubicin 4Cytarabine 4Brentuximab Vedotin 4ibrutinib 3Specimen Handling 3Dexamethasone 3Crizotinib 3tisagenlecleucel 2tafasitamab 2polatuzumab vedotin 2pirtobrutinib 2pegaspargase 2idelalisib 2duvelisib 2axicabtagene ciloleucel 2avapritinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Cobicistat × Lymphoid × Clear all
NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡